VJDementia is committed to improving our service to you

Share this video  

VJDementia is committed to improving our service to you

ARUK 2019 | Etanercept and microglial activation in mild cognitive impairment

Alexander Gerhard, MD, of the University of Manchester, Manchester, UK, discusses the placebo-controlled study of etanercept, a TNFα inhibitor, on microglial activation in patients with mild cognitive impairment. Speaking at the Alzheimer’s Research UK (ARUK) Conference 2019, held in Harrogate, UK, Dr Gerhard goes on to explain why this research ended early and discusses what research into etanercept he would like to pursue.